SCHEMBL6440700

SCHEMBL6440700

CCOC(COc1cccc(-c2ccc(C3CCN(S(=O)(=O)C(C)(C)C(=O)OC)CC3)cc2C)c1)OCC

nearest known ligand 0.71

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 10/20 0.71
MMP3 P08254 10/20 0.71
MMP1 P03956 2/20 0.65
MMP9 P14780 2/20 0.65
MMP14 P50281 2/20 0.65
PRMT5 O14744 2/20 0.37
WDR77 Q9BQA1 2/20 0.37
USP5 P45974 1/20 0.34
DHODH Q02127 2/20 0.34
MMP13 P45452 1/20 0.34
CYP3A4 P08684 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
CHRM3 P20309 1/20 0.33
JAK2 O60674 1/20 0.32
JAK3 P52333 1/20 0.32
PTK2 Q05397 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6587846 0.92 MMP2 (0.83) MMP2MMP3MMP1MMP9MMP14
SCHEMBL6971954 0.89 MMP2 (0.68) MMP2MMP3MMP1MMP9MMP14
SCHEMBL6971949 0.89 MMP2 (0.68) MMP2MMP3MMP1MMP9MMP14
SCHEMBL6586333 0.87 MMP2 (0.85) MMP2MMP3MMP1MMP9MMP14
SCHEMBL6436990 0.86 MMP3 (0.69) MMP2MMP3MMP1MMP9MMP14
SCHEMBL6434351 0.86 MMP2 (0.84) MMP2MMP3MMP1MMP9MMP14
SCHEMBL6437562 0.86 MMP2 (0.84) MMP2MMP3MMP1MMP9MMP14
SCHEMBL6432618 0.85 MMP2 (0.67) MMP2MMP3MMP1MMP9MMP14
SCHEMBL6585861 0.84 MMP3 (0.60) MMP2MMP3MMP1MMP9MMP14
SCHEMBL6588374 0.84 MMP2 (0.70) MMP2MMP3MMP1MMP9MMP14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050026836-A1 Composition for the treatment of damaged tissue DACK KEVIN NEIL (GB) 2005-02-03 US disclosed
US-20030199440-A1 Composition for the treatment of damaged tissue PFIZER INC. 2003-10-23 US disclosed
EP-1181017-B1 METALLOPROTEASE INHIBITORS PFIZER LTD (GB) 2003-04-16 EP disclosed
US-6511993-B1 Substituted alpha-aminosulphonyl-acetohydroxamic acids which are inhibitors of zinc-dependent metalloprotease enzymes PFIZER INC. 2003-01-28 US disclosed
EP-1242120-A2 COMBINATIONS OF GROWTH FACTORS AND I:UPA OR I:MMP FOR THE TREATMENT OF DAMAGED TISSUE Pfizer Limited (GB) 2002-09-25 EP disclosed
EP-1181017-A1 METALLOPROTEASE INHIBITORS Pfizer Limited (GB) 2002-02-27 EP disclosed
WO-2001049309-A2 COMBINATIONS OF GROWTH FACTORS AND I: UPA OR I: MMP FOR THE TREATMENT OF DAMAGED TISSUE PFIZER LIMITED (GB) 2001-07-12 WO disclosed
WO-2000074681-A1 METALLOPROTEASE INHIBITORS PFIZER LIMITED (GB) 2000-12-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199440-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 MMP2 19/4885MMP3 28/4885MMP1 1/4885
US-20050026836-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 MMP2 19/4885MMP3 28/4885MMP1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.